Novartis unveiled a planned $23 billion investment over five years in U.S.-based infrastructure, with the goal of “ensuring all key Novartis medicines for U.S. patients will be made in the United States.”
According to Novartis, the investments ensure that the company will have U.S. manufacturing capacity for all its core technology platforms, including small molecules, biologics and cutting-edge platforms like gene and cell therapy and radioligand therapies manufacturing. The investment will bring internal manufacturing of Novartis’ siRNA technology to the U.S. for the first time.
With new manufacturing capacity, Novartis says it will be able to produce 100% of its key medicines end-to-end in the U.S.
This commitment will include building seven new U.S. facilities, creating nearly 1,000 new jobs at Novartis. The production capacity will cover both APIs and biologics drug substance, as well as secondary production and packaging.
Specifically, over the next five years, Novartis will:
- Establish a $1.1 billion biomedical research innovation hub in San Diego, California, expected to open between 2028 and 2029.
- Build four new manufacturing facilities in soon-to-be-determined states, including three that will make biologics drug substances, drug products, device assembly and packaging, and one facility that will make chemical drug substances, oral solids dosage forms and packaging.
- Build two new radioligand therapy manufacturing facilities in Florida and Texas.
- Expand three radioligand therapy manufacturing facilities in Indianapolis, Indiana; Millburn, New Jersey; and Carlsbad, California.
Novartis’ push to step up manufacturing investments in the U.S. comes shortly after President Trump revealed his ‘Liberation Day’ tariffs, and follows moves from pharma giants Pfizer and Merck & Co.